A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Upadacitinib (Primary) ; Corticosteroids
Indications Atopic dermatitis
Focus Registrational; Therapeutic Use
Acronyms AD Up
Sponsors AbbVie; AbbVie Germany; Sumitomo Pharma America

Most Recent Events

02 May 2024 Results (n=901) assessing analysis of efficacy and safety of Upadacitinib published in the Journal of Dermatological Treatment.
11 Apr 2024 Planned number of patients changed from 890 to 1500.
11 Oct 2023 According to AbbVie media release, data from this study will be orally presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight